Patrick Campbell

Prespecified analysis of 320 patients in VISIONARY were presented at ERA 2025 Congress.

Combination therapy with finerenone and empagliflozin significantly reduces urinary albumin levels in CKD patients.

New 100-week data reveals zigakibart's significant efficacy and safety in reducing proteinuria for IgA nephropathy.

Get an overview of the top stories from May 2025 in endocrinology in our monthly recap!

An overview of the 7 presentations included as late-breaking clinical trials at ERA 2025.

Discover key advancements and setbacks in cardiovascular medicine from May 2025, shaping the future of cardiometabolic care and treatment options.

The May 30, 2025 SOCS News Update highlights cosmetic concerns among patients with skin of color.

New data reveal tirzepatide significantly outperforms semaglutide in weight loss.

Data from nearly half a dozen trials suggests steroidal MRAs may provide little benefit in kidney transplant patients.

The study evaluated more than 450 patient visits and concluded AI decision support could improve adherence to guideline-adherent care recommendations.

The Best Practice Advice is aimed at detailing benefits and harms of cannabis or cannabinoids in the management of chronic noncancer pain.

A recap of 10 clinical trials in cardiovascular care to know from the American College of Cardiology 2025 Scientific Sessions.

The approval indicates Novartis's atrasentan (Vanrafia) for proteinuria reduction in primary IgA nephropathy.

Our Q1 2025 recap for endocrinology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in diabetes care.

Despite failing to achieve significance for its primary endpoint, investigators suggest the trial further demonstrates the potential of cell therapy in HFrEF.

Phase 2 data at ACC.25 provide further insight into the effects of lepodisiran on serum Lp(a) and other biomarkers of risk.

FARES-II trial shows 4-factor PCC is safer, reduces bleeding, transfusions, and complications vs frozen plasma in cardiac surgery.

Data from the REVERSE-IT trial provide vital insight into the efficacy and safety of bentracimab as an FDA decision looms on the horizon.

The WARRIOR trial provides insight into intensive medical therapy in women with INOCA, but investigators caution limitations hinder the applicability of results.

Data from STRIDE at ACC.25 demonstrate semaglutide could provide even greater benefits in type 2 diabetes than previously known.

Announced on March 28, 2025, the FDA's CRL to Milestone Pharmaceuticals cites CMC issues, but no issues with safety or efficacy data.

The FDA approval of diazoxide choline extended-release tablets (Vykat XR) was announced on March 26, 2025.

The March 2025 approval for iptacopan marks the first for C3 glomerulopathy and is based on the APPEAR-C3G trial.

The approval for moderately to severely active Crohn disease marks the fourth indication for Johnson and Johnson's IL-23 inhibitor.

A recap of the 7 phase 3 trials presented during the 2025 AAD annual meeting's late-breaking sessions.

An analysis of data from the DELTA program at AAD 2025 sheds light on the efficacy of delgocitinib for chronic hand eczema.

Data at AAD 2025 and an announcement from Amgen provide insight into the potential role of rocatinlimab in atopic dermatitis.

New data from AAD 2025 and topline results from the ICONIC program underline the potential of icotrokinra in moderate to severe plaque psoriasis.

LIBERTY-BP ADEPT provides further insight into the potential of dupilumab in bullous pemphigoid ahead of the June 2025 PDUFA date.